Clinical Trial Update: HER2 Expression of HER2 Affibody-based PET/CT to Predict Response in Bladder Cancer Patients Treated With ADC [NA]

View source ↗

Summary

A clinical trial is evaluating whether HER2-affibody-based PET/CT imaging can predict response to an antibody-drug conjugate in bladder cancer patients and is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• Antibody-drug conjugate (ADC)
• HER2 affibody-based PET/CT imaging agent

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: HER2 Positive or Suspicious Positive Tumors | NA | Status: RECRUITING